Key result
An in vitro assay demonstrated that recombination can occur within non-deoptimized viral genomic regions between wild-type and codon deoptimized FMDV strains, with recombinants being less fit than WT.
Why the study?
Reversion to virulence or loss of DIVA markers via potential recombination between codon-deoptimized foot-and-mouth disease live-attenuated vaccine candidates and wild-type strains had not yet been analyzed.
An in vitro assay successfully quantitated recombination between wild-type and codon-deoptimized FMDV strains, demonstrating that recombinants with large deoptimized stretches are less fit than wild-type viruses.
In vitro recombination assay for FMD LAVs warrants caution before field use; leaves open in vivo reversion risk with wild-type strains.
Codon deoptimization (CD) has been recently used as a possible strategy to derive foot-and-mouth disease (FMD) live-attenuated vaccine (LAV) candidates containing DIVA markers. However, reversion to virulence, or loss of DIVA, from possible recombination with wild-type (WT) strains has yet to be analyzed. An in vitro assay was developed to quantitate the levels of recombination between WT and a prospective A24-P2P3 partially deoptimized LAV candidate. By using two genetically engineered non-infectious RNA templates, we demonstrate that recombination can occur within non-deoptimized viral genomic regions (i.e., 3'end of P3 region). The sequencing of single plaque recombinants revealed a variety of genome compositions, including full-length WT sequences at the consensus level and deoptimized sequences at the sub-consensus/consensus level within the 3'end of the P3 region. Notably, after further passage, two recombinants that contained deoptimized sequences evolved to WT. Overall, recombinants featuring large stretches of CD or DIVA markers were less fit than WT viruses. Our results indicate that the developed assay is a powerful tool to evaluate the recombination of FMDV genomes in vitro and should contribute to the improved design of FMDV codon deoptimized LAV candidates.
No takes yet. Share an insight, caveat, or question.
Spinard et al. (2023) studied Foot-and-mouth disease (FMD). Codon deoptimized FMDV strains (A24-P2P3 partially deoptimized LAV candidate) vs. Wild-type (WT) strains was evaluated on Levels of recombination between WT and prospective A24-P2P3 partially deoptimized LAV candidate. An in vitro assay demonstrated that recombination can occur within non-deoptimized viral genomic regions between wild-type and codon deoptimized FMDV strains, with recombinants being less fit than WT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: